We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nymox Pharmaceutical Corp (NYMXF) Common Stock USD NPV

Sell:$0.35 Buy:$0.35 Change: $0.0165 (4.49%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.0165 (4.49%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.0165 (4.49%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.

Contact details

St. Laurent
9900 Cavendish Blvd Suite 306
H4M 2V2
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$35.91 million
Shares in issue:
93.27 million
Off Exchange
US dollar

Key personnel

  • Paul Averback
    Chairman of the Board, President, Chief Executive Officer
  • Christopher Riley
    Chief Financial Officer
  • Patrick Doody
    Vice President, General Counsel, Director
  • Randall Lanham
    General Counsel, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.